amoxicillin-potassium-clavulanate-combination and Polycystic-Kidney--Autosomal-Dominant

A 41 years old woman with diagnosis of ADPKD had been in treatment with tolvaptan for 16 weeks when an elevation of liver enzyme levels was detected. She had taken autonomously amoxicillin/clavulanic acid (in doses of 825/175 mg twice a day for 7 days) about 5 weeks before. The timing of the event and the kind of hepatocellular injury could be attributed to the concomitance of medication of tolvaptan and amoxicillin/clavulanic acid.. We highlight the need to careful monitor hepatic enzyme levels in order to recognize early hepatic side effects in ADPKD patients in treatment with tolvaptan and amoxicillin/clavulanic acid.

Topics: Adult; Alanine Transaminase; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Antidiuretic Hormone Receptor Antagonists; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Liver; Polycystic Kidney, Autosomal Dominant; Tolvaptan